Scientist-founders often believe one more experiment will prove their hypothesis. To succeed as a CEO, they must shift from scientific curiosity to ruthless capital discipline, killing unviable programs and building a team that challenges ideas, not just executes them.

The true value of early R&D isn't hitting a precise, long-range target, which is often based on an outdated business case. Instead, measure its value by how effectively it preserves and creates future optionality. Each step should intentionally reduce uncertainty and narrow down choices, rather than just following a rigid path.

While no single path guarantees startup success, the phrase "there's no one right answer" is dangerous. It implies all approaches are equally valid, leading founders to choose easy methods over proven, difficult ones. In reality, only a handful of paths are viable, while the vast majority ensure failure.

Engineers must resist the urge to strive for technical perfection. The optimal solution is one that fits the current business context, whether that's preparing for a funding round, an acquisition, or a commercial launch. Knowing when 'good enough' is sufficient is a critical business skill.

In biotech, early data is often ambiguous. Instead of judging programs on potential, leaders must prioritize based on the time and capital required to reach a clear 'yes' or 'no' outcome. Indefinite 'gray zone' projects drain resources that could fund a winner.

Resvita Bio's CEO notes that in academia, scientists conduct numerous experiments to prove a single point for publication. In a startup, the focus shifts to building momentum. Once a concept is proven, the team must immediately move to the next challenge rather than over-verifying with redundant experiments.

Many scientists are driven by pure curiosity. However, the mindset that pushes an academic toward entrepreneurship is a relentless focus on reaching a definitive conclusion—a 'yes or no' answer. This goal-oriented drive to translate a concept into a real-world application is a key founder trait in biotech.

Randomly testing new ideas under the 'fail fast' mantra is inefficient and costly. Instead, experimentation should be guided by a high-level business goal or question. This 'compass' focuses efforts, ensuring that even failures produce valuable, relevant learnings rather than just being expensive dead ends.

Founders must balance scientific conviction with market feedback. Kulkarni shares that his team abandoned pursuing certain indications that, while scientifically sound, failed to gain investor traction. This shows the critical need to pivot based on market signals, not just internal belief, to ensure continued funding and support.